Optimisation of Mo doping to form NiCoMo ternary sulphides for high performance charge storage.

Multi-component synergy and the rational design of structures are effective methods for preparing electrode materials for high-performance energy storage devices. Transition metal-based hydroxides offer advantages such as a large specific surface area, large interlayer spacing, multiple redox states, and high theoretical capacity, making them commonly used as positive materials for supercapacitors. However, challenges like low conductivity and severe agglomeration limit their practical application. This study focuses on the preparation of Ni, Co, and Mo ternary transition metal hydroxides by incorporating the Mo element to optimize their structure. Furthermore, sulfide ions were utilized in an ion exchange process to replace hydroxides, resulting in the formation of NiCoMo ternary sulfide electrode materials. By adjusting the amount of Mo added, a spherical nanoneedle-shaped N2C1MS0.2-2 electrode material was successfully synthesized. This electrode exhibited a specific capacity of 2094 F g-1 at a current density of 1 A g-1. In addition, an asymmetric supercapacitor was assembled with activated carbon as the negative electrode and N2C1MS0.2-2 as the positive electrode, which had an energy density of 46.2 W h kg-1 at a power density of 800 W kg-1, a capacity retention of 89.7% and a coulombic efficiency of 97.8% after 10 000 cycles. This study provides a reference for the design and preparation of ternary sulphide electrode materials.

Etching-induced ion exchange engineering of two-dimensional layered NiFeCo-based hydroxides for high energy charge storage.

Efficient and rapid synthesis of transition metal-based hydroxides with tailored microstructures has emerged as a promising approach to fabricate high-performance electrode materials for energy storage devices. However, many conventional synthesis methods are cumbersome, expensive and time-consuming, and the microstructures of electrode materials are usually uncontrollable. Herein, we propose a fast and cost-effective approach to electrochemically in situ grow NiFeCo-based ternary hydroxides (NiFeCo-THs) with layered nanosheet structures on pretreated nickel foam (NF). The in situ grown NiFeCo-THs were in direct contact with the NF to form a monolithic electrode as NiFeCo/NF. By engineering the ion exchange process for controlling the ionic ratio, the monolithic Ni1(Fe/Co = 1/1)0.5/NF electrode was fabricated and found to show the optimum electrochemical behavior with a specific capacitance of 2.32 C cm-2 at 2 mA cm-2 as a result of its characteristic microstructures. Furthermore, a hybrid supercapacitor was constructed utilizing the monolithic Ni1(Fe/Co = 1/1)0.5/NF electrode and activated carbon as the cathode and anode, respectively, and it was found to have an energy density of 81.1 µW h cm-2 at a power density of 808.8 µW cm-2. After 5000 cycles, 84.0% of the initial capacitance of the hybrid supercapacitor was maintained, and the monolithic Ni1(Fe/Co = 1/1)0.5/NF electrode still retained the arrayed nanosheet structure.

Design of a Zn-based nanozyme injectable multifunctional hydrogel with ROS scavenging activity for myocardial infarction therapy.

The existing strategies for myocardial infarction therapy mainly focus on reinstating myocardial blood supply, often disregarding the intrinsic and intricate microenvironment created by elevated levels of reactive oxygen species (ROS) that accompanies myocardial infarction. This microenvironment entails cardiomyocytes apoptosis, substantial vascular cell death, excessive inflammatory infiltration and fibrosis. In such situation, the present study introduces a zinc-based nanozyme injectable multifunctional hydrogel, crafted from ZIF-8, to counteract ROS effects after myocardial infarction. The hydrogel exhibits both superoxide dismutase (SOD)-like and catalase (CAT)-like enzymatic activities, proficiently eliminating surplus ROS in the infarcted region and interrupting ROS-driven inflammatory cascades. Furthermore, the hydrogel's exceptional immunomodulatory ability spurs a notable transformation of macrophages into the M2 phenotype, effectively neutralizing inflammatory factors and indirectly fostering vascularization in the infarcted region. For high ROS and demanding for zinc of the infarcted microenvironment, the gradual release of zinc ions as the hydrogel degrades further enhances the bioactive and catalytic performance of the nanozymes, synergistically promoting cardiac function post myocardial infarction. In conclusion, this system of deploying catalytic nanomaterials within bioactive matrices for ROS-related ailment therapy not only establishes a robust foundation for biomedical material development, but also promises a holistic approach towards addressing myocardial infarction complexities. STATEMENT OF SIGNIFICANCE: Myocardial infarction remains the leading cause of death worldwide. However, the existing strategies for myocardial infarction therapy mainly focus on reinstating myocardial blood supply. These therapies often ignore the intrinsic and intricate microenvironment created by elevated levels of reactive oxygen species (ROS). Hence, we designed an injectable Zn-Based nanozyme hydrogel with ROS scavenging activity for myocardial infarction therapy. ALG-(ZIF-8) can significantly reduce ROS in the infarcted area and alleviate the ensuing pathological process. ALG-(ZIF-8) gradually releases zinc ions to participate in the repair process and improves cardiac function. Overall, this multifunctional hydrogel equipped with ZIF-8 makes full use of the characteristics of clearing ROS and slowly releasing zinc ions, and we are the first to test the therapeutic efficacy of Zinc-MOFs crosslinked-alginate hydrogel for myocardial infarction.

Short-chain fatty acids regulate erastin-induced cardiomyocyte ferroptosis and ferroptosis-related genes.

Background: Ferroptosis has been proven to contribute to the progression of myocardial ischemia/reperfusion (I/R) injury and can be inhibited or promoted by ATF3. Short-chain fatty acids (SCFAs) have shown benefits in various cardiovascular diseases with anti-inflammatory and antioxidant effects. However, the impact of SCFAs on ferroptosis in ischemic-stimulated cardiomyocytes remains unknown. This study aimed to investigate the effect of SCFAs on cardiomyocyte ferroptosis, the expression of ATF3, and its potential upstream regulators. Methods and results: The expression of ATF3, ferroptosis pathway geneset (FPG), and geneset of potential regulators for ATF3 (GPRA, predicted by the PROMO database) was explored in the public human myocardial infarction single-cell RNA-seq (sma) dataset. Cardiomyocyte data was extracted from the dataset and re-clustered to explore the FPG, ATF3, and GPRA expression patterns in cardiomyocyte subclusters. A dose-dependent toxic experiment was run to detect the suitable dose for SCFA treatment. The erastin-induced ferroptosis model and hypoxia-reoxygenation (H/R) model (10 h of hypoxia followed by 6 h of reoxygenation) were adopted to assess the effect of SCFAs via the CCK8 assay. Gene expression was examined via RT-PCR and western blot. Ferroptosis markers, including lipid peroxides and Fe2+, were detected using the liperfluo and ferroOrange probes, respectively. In the sma dataset, upregulated ferroptosis pathway genes were mainly found in the infarction-stimulated cardiac cells (border zone and fibrotic zone), particularly the cardiomyocytes and adipocytes. The ATF3 and some of its potential transcription factors (VDR, EGR3, PAX5, and SP1) can be regulated by SCFA. SCFA can attenuate erastin-induced lipid peroxidation in cardiomyocytes. SCFA treatment can also reverse erastin-induced Fe2+ increase but may strengthen the Fe2+ in the H/R model. We also precisely defined a ferroptosis subcluster of cardiomyocytes (CM09) that highly expressed FPG, ATF3, and GPRA. Conclusion: The ATF3 and the ferroptosis pathway are elevated in cardiomyocytes of injury-related cardiac regions (border zone, ischemic zone, and fibrotic zone). SCFA can attenuate cardiomyocyte ferroptosis and regulate the expression of ATF3. Our study offers novel insights into the potential targets of SCFAs in the cardiovascular system.